Trial · NCT05922436
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
NCT05922436, Phase 3, Unknown, Qilu Pharmaceutical (Hainan) Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency. Trials, record NCT05922436. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05922436
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
- NCT number
- NCT05922436
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 378 participants, estimated
- Lead sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Conditions
- Hypertensive Emergency
- Interventions
- QLG2071, Cleviprex®
- First posted
- 2023-06-28
- Last updated
- 2023-06-28
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the percentage of patients who reach the target range (Systolic Blood Pressure decreased by ≥15% and ≤25% from baseline) within 30 minutes of administration | Within 30 minutes of the initiation of the infusion | Proportion of patients who reach the target range within 30 minutes of administration |
| Secondary | The time for the first SBP fell within the target range (SBP decreased by ≥15% and ≤25% from baseline) within 30 minutes of administration | Within 30 minutes of the initiation of the infusion | The time for the first SBP fell within the target range (SBP decreased by ≥15% and ≤25% from baseline) within 30 minutes of administration |
| Secondary | Proportion of patients successfully converted to oral antihypertensive therapy within 6 hours of discontinuation | within 6 hours of discontinuation | Proportion of patients successfully converted to oral antihypertensive therapy within 6 hours of discontinuation |
| Secondary | Change in heart rate | within 30 minutes of administration | Change of heart rate from baseline within 30 min of administration |
| Secondary | Time to attainment of the 30-minute SBP target range | within 30 minutes of administration | Time to attainment of the 30-minute SBP target range |
| Other | Incidence of adverse events (AEs) | Throughout the study period,up to 4 days | Incidence of adverse events (AEs) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05922436
GET https://conductscience.org/api/trials/v1/NCT05922436/registered